Regeneron Pharmaceuticals Inc. filings document the regulatory disclosures of a biotechnology operating company with marketed medicines, clinical programs and collaboration-driven research activity. Recent Form 8-K reports furnish quarterly and annual financial and operating results, including GAAP and non-GAAP measures, product sales commentary, regulatory and pipeline updates, and acquired in-process research and development charges tied to collaboration, licensing and asset-acquisition activity.
The company's proxy materials cover governance and executive compensation matters, including pay-versus-performance data and equity award disclosures. Regeneron's SEC record also includes exhibit filings and Inline XBRL cover-page data associated with material-event reports, providing formal documentation of financial reporting, corporate governance and capital-allocation disclosures such as share repurchase authorization.
Regeneron Pharmaceuticals, Inc. Co-Chief Scientific Officer Andrew J. Murphy sold 4,147 common shares on October 14, 2026, at reported prices ranging from $753.76 to $781.47 per share. These dispositions and the acquisition were made pursuant to a plan intended to comply with Rule 10b5-1(c), adopted May 7, 2026.
On October 13, Murphy exercised options for 17,000 shares at $381.92 per share; 12,853 shares were delivered or withheld for payment of exercise price or tax liability. The filing also reports 4,414 shares held indirectly by the 401(k) Plan.
Regeneron Pharmaceuticals, Inc. officer Andrew J. Murphy filed a notice of a proposed sale of 4,147 common shares, with an aggregate market value of $3,204,379.85, through UBS Financial Services, Inc. on Nasdaq, approximately October 14, 2026. The notice also lists 4,174 common shares acquired from the issuer on October 13, 2026, through exercise of stock options in a net exercise.
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi Biotechnology SAS and Sanofi amended their antibody collaboration to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting IL-13, IL-4, IL-4Rα, and IL-4xIL-13. Sanofi will pay Regeneron $1.0 billion upfront; Regeneron may receive up to $7.0 billion in aggregate milestone payments upon achievement of development, regulatory, and commercial milestones.
Global profits from the new products and development costs under the Antibody LCA will be shared equally; Regeneron bears costs above a budget cap for the new products, subject to certain future recoupment rights. Regeneron may add Sanofi’s Phase 2/3 lunsekimig and another early-development product asset by asset after completion of certain ongoing clinical trials, reimbursing certain development costs if it exercises an option. The parties also entered a settlement under which Regeneron agreed to dismiss its lawsuit over access to commercialization information and audit rights under the Antibody LCA.
Regeneron currently expects a preliminary, unaudited third-quarter 2026 acquired IPR&D charge of approximately $22 million pre-tax, with an expected approximately $0.18 negative impact on both GAAP and non-GAAP net income per diluted share. Results remain subject to financial statement closing procedures, and actual results may differ.
Regeneron Pharmaceuticals granted one-time PSUs to Board co-chairs Leonard S. Schleifer, president and CEO, and George D. Yancopoulos, president and chief scientific officer, effective September 24, 2026. The awards replace their annual equity awards until 2036 and depend on product filings and approvals, new-product revenues and relative TSR over the 10-year period from January 1, 2026 through December 31, 2035. Maximum earnouts are capped at 2,700,000 PSUs for the CEO and 2,900,000 for the CSO. No revenue-based PSUs may be earned before certification of 2032 revenue or when new-product annual revenues are below $10 billion. The top revenue target is nearly $30 billion; $40 billion in fiscal 2034 or 2035 may also satisfy the maximum earnout if absolute TSR is positive and exceeds the NASDAQ Biotechnology Total Return Index.
Shares delivered before the performance period ends carry a 20% holdback and cannot be sold until February 2036, except for death, disability or a change in control. Voluntary departure or retirement forfeits unvested PSUs; succession plans are due by the fifth grant anniversary or a later date set by the Board. A newly formed majority-owned subsidiary exploring a potential non-core opportunity has nominal value, no significant assets and has not commenced operations; both executives received partly vesting equity stakes.
REGENERON PHARMACEUTICALS, INC. (REGN) executive vice president of Commercial, Marion McCourt, reported open-market sales of company common stock under a Rule 10b5-1 trading plan. On September 3, 2026, she sold 1,131 shares at $857.39 per share, and on September 2, 2026, she sold 1,215 shares at $850.00 per share. A separate entry reports 219 shares of common stock held indirectly through a 401(k) plan as of September 2, 2026.
REGENERON PHARMACEUTICALS, INC. (REGN) director Kathryn Guarini reported option-related transactions in the company’s stock. On September 2, 2026, she exercised options for 400 shares at an exercise price of $719.37 per share and sold 400 shares at $850.00 per share, under a Rule 10b5-1(c) trading plan adopted on February 13, 2026. Following the option exercise, she continued to hold options covering 1,158 shares of common stock.
REGENERON PHARMACEUTICALS, INC. (REGN) is named as the issuer in a Rule 144 notice covering a proposed sale of common stock for the account of officer Marion McCourt. The notice relates to 1,131 shares, to be sold through UBS Financial Services Inc. on NASDAQ.
The shares were acquired from the issuer via RSA vesting on December 12, 2023. The filing also lists a prior sale by Marion McCourt of 1,215 shares of common stock during the past three months.
REGENERON PHARMACEUTICALS, INC. (REGN) reports that company officer Marion McCourt has filed a notice under Rule 144 to sell up to 1,215 shares of Regeneron common stock through UBS Financial Services Inc. on or after September 2, 2026 on NASDAQ. The shares relate to vested restricted stock awards from February 12, 2023, December 9, 2024, and December 16, 2024, with an aggregate value of $1,032,750 reported in the notice.
REGENERON PHARMACEUTICALS, INC. (REGN) is named as the issuer in a Form 144 notice covering a proposed sale of its common stock by director Kathryn Guarini. The notice reports a planned sale of 400 shares of common stock on or after September 2, 2026, with an aggregate market value of $340,000, to be effected through UBS Financial Services Inc.
The shares are indicated as being issuable upon the exercise of a stock option on September 2, 2026, for cash. The filing also reports that Guarini sold 400 shares of Regeneron common stock on August 10, 2026, with an aggregate market value of $320,000, during the prior three months.
REGENERON PHARMACEUTICALS, INC. (REGN) reported insider equity transactions by Joseph J. LaRosa, EVP General Counsel and Secretary. On 2026-08-19, he exercised a non-qualified stock option for 12,282 shares of common stock at an exercise price of $381.92 per share, from an award that vested in four equal annual installments commencing one year after grant. He acquired 12,282 common shares upon exercise and 9,019 shares of common stock at $830.15 per share were delivered or withheld for payment of exercise price or tax liability. Following the transaction, he directly held 12,283 non-qualified stock options expiring on 2026-12-16 and indirect common stock holdings of 3,402 shares via a 2024 GRAT, 5,407 shares via a 2025 GRAT, and 413 shares through a 401(k) plan.